| Name | Title | Contact Details |
|---|
Mountain View Pharmaceuticals is a Menlo Park, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Soley Therapeutics is a San Francisco-based, privately-held biotechnology company that is combining artificial intelligence with unique proprietary molecular and cellular response detection for discovering and developing new efficacious drugs, using image acquisition-based approaches. We have translated decades of research by Soley`s co-founders on cell-responses to perturbations and resulting information-flow within the cell, into quantifiable high-resolution imaging to identify and accelerate the development of novel therapeutic molecules for complex diseases.
DermTech International is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Better Therapeutics ("Better") is developing first-in-class prescription digital therapeutics to deliver behavioral therapy to patients. Led by an experienced team of biotechnology executives with funding from top-tier industry investors, Better expects to go public through a merger with SPAC Mountain Crest Acquisition Corp. (NASDAQ: MCAD) during the summer of 2021. Better was founded upon the realization that nearly half a trillion dollars are spent each year treating the symptoms or effects of cardiometabolic diseases while little is being done to address the behaviors that cause them. Better has created prescription software that it believes has the opportunity to fundamentally change the treatment of a broad range of cardiometabolic diseases beginning with type 2 diabetes. The team is focused on creating significant patient impact through the launch of their first product in 2023. Better is developing a portfolio of regulated software products that treat the root causes of disease, improving the health and quality of life of patients while giving providers and payers access to cost-effective digital behavior therapies.
Talaris Therapeutics is a late-clinical stage biotechnology company based in Boston, MA and Louisville, KY. Talaris is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe auto-immune and immune-mediated disorders. The company was founded on technology discovered and developed by Dr. Suzanne Ildstad and operates its own cell processing facility in Louisville. Talaris is backed by leading life sciences investors Blackstone Life Sciences, Longitude Capital and Qiming Venture Partners USA.